Endocrinology

Episodes 1-3 of 3

• • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Charles P. Vega, MD

    Peer

  5

  CME/CE Broadcast Replay

  

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credits

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credits

• • 

    

    Peter Rossing, DMSc, MD

    Peer

  • 

    

    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)

    Peer

  • 

    

    Matthew R. Weir, MD

    Peer

  10

  

  RestartResume

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  RestartResume

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  0.25 credits

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  0.25 credits

• • 

    

    Robert J. Chilton, DO

    Peer

  • 

    

    John R. Nelson, MD, FACC, FNLA, FASNC

    Peer

  7

  

  RestartResume

  Clinicians' Update on Omega-3s in ASCVD Risk Reduction  

  RestartResume

  Clinicians' Update on Omega-3s in ASCVD Risk Reduction  

  1.00 credits

  Clinicians' Update on Omega-3s in ASCVD Risk Reduction  

  1.00 credits